Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma

Bevacizumab is a recombinant humanised monoclonal antibody directed against the vascular endothelial growth factor (VEGF). The drug, alone or in combination with other anticancer agents, has been shown to be effective against several types of neoplasms. We report a case of a woman with a history of...

Descripción completa

Detalles Bibliográficos
Autores principales: Graceffa, D., Maiani, E., Pace, A., Solivetti, F. M., Elia, F., De Mutiis, C., Bonifati, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517839/
https://www.ncbi.nlm.nih.gov/pubmed/23243547
http://dx.doi.org/10.1155/2012/208606
Descripción
Sumario:Bevacizumab is a recombinant humanised monoclonal antibody directed against the vascular endothelial growth factor (VEGF). The drug, alone or in combination with other anticancer agents, has been shown to be effective against several types of neoplasms. We report a case of a woman with a history of severe psoriasis who developed psoriatic arthritis during a course of bevacizumab, which was administered for a malignant glioma.

Ejemplares similares